VERU-111 analogs
- Generic Name
- VERU-111 analogs
Veru's Enobosarm Shows Promise in Phase IIb Trial for Enhanced Weight Management
• Phase IIb QUALITY trial demonstrates significant improvements in lean mass retention and fat loss when combining enobosarm with semaglutide, compared to placebo.
• The study reports 80.6% of treated patients maintained stair climb power near baseline, indicating enhanced functional benefits particularly relevant for older populations.
• Higher 6mg dose of enobosarm showed superior improvements in fat loss metrics, prompting plans for Phase III program development.
Veru's Enobosarm Shows Promise in Preserving Muscle Mass During Weight Loss with GLP-1 RAs
• Veru Inc. announced positive topline results from its Phase 2b QUALITY study, where enobosarm significantly reduced lean mass loss in patients on WEGOVY.
• Patients on enobosarm lost 71% less lean mass and 27% more fat mass compared to those receiving WEGOVY alone, indicating improved body composition.
• The study met its primary endpoint, showing a statistically significant benefit in preserving total lean body mass with enobosarm plus semaglutide versus placebo plus semaglutide.
• Veru plans to meet with the FDA to discuss the design of a Phase 3 clinical program based on these promising results.
Veru Inc. Initiates Phase 2b Trial of Enobosarm for Sarcopenic Obesity and Sells FC2 Business
• Veru Inc. has commenced its Phase 2b QUALITY trial, evaluating enobosarm combined with semaglutide for sarcopenic obesity, with 168 patients enrolled.
• The QUALITY trial is a multicenter, double-blind, placebo-controlled study assessing enobosarm's safety and efficacy in preserving muscle and augmenting fat loss in elderly patients.
• Veru Inc. sold its FC2 Female Condom business for US$18 million to Riva Ridge Capital Management, aiming to focus on biopharmaceutical development.
• The sale is projected to provide approximately US$12.5 million in proceeds, strengthening Veru's financial position for clinical trials of enobosarm.
Veru's Enobosarm Shows Potential in Meta-Analysis to Optimize Weight Loss by Preserving Muscle
• A meta-analysis of four randomized clinical trials suggests that enobosarm may optimize weight loss by preserving muscle mass.
• Veru Inc. is conducting a Phase 2b trial to evaluate enobosarm's safety and efficacy in sarcopenic obese or overweight elderly patients receiving semaglutide.
• Topline results from the Phase 2b trial are expected in January 2025, with extension study results anticipated in Q2 2025.
• Enobosarm has a large safety database of 27 clinical trials involving 1581 men and women and was generally well tolerated with no increases in gastrointestinal side effects.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath